bioprocessing
(6)
Made Scientific
Made Scientific is a Princeton, New Jersey-based contract development and manufacturing organization (CDMO) focused exclusively on cell therapies. Formerly BioCentriq, it was rebranded in March 2025 and is backed by South Korea's GC Corporation. The company runs a 60,000 sq. ft. GMP facility with five ISO 7 / Grade B cleanrooms, offering process and analytical development, GMP manufacturing of autologous and allogeneic products, aseptic fill and finish, QC release testing, regulatory consulting, and workforce training, taking cell therapy programs from preclinical development through commercial supply.
Terragia Biofuel
Terragia Biofuel is a New Hampshire climate-tech startup turning non-food plant waste into cost-competitive, low-carbon ethanol using engineered thermophilic bacteria. Its consolidated bioprocessing (CBP) approach skips the expensive enzymes and thermochemical pretreatment that have historically sunk cellulosic biofuel economics, promising an 8x shorter payback period at 10x smaller scale. Spun out of Professor Lee Lynd's decades of research at Dartmouth, Terragia aims to make biofuels for hard-to-electrify transport - aviation, shipping, and long-haul trucking - that can actually compete with fossil fuels.
Matterworks
Matterworks is a Somerville, Massachusetts biotech-AI company building foundation models for molecular biology. Its Large Spectral Models (LSMs) are trained on billions of mass spectrometry spectra and read raw molecular signals directly, turning slow, manual mass-spec workflows into automated, untargeted absolute quantitation. Its flagship cloud platform, Pyxis, acts as a predictive omics assistant that converts raw LC-MS data into identified, quantified molecules and biological insight - making mass spectrometry usable by any biologist rather than only specialist analysts.
Solarbiotech
Solarbiotech is a U.S.-based synthetic biology and biomanufacturing company that helps companies move precision-fermentation products from lab bench to commercial scale. Built around a Norton, Virginia plant with fermentation capacity from 6L to 10,000L and a modular 'BioNodes' architecture, it offers end-to-end strain-to-shelf services - upstream fermentation, downstream processing, and commercial production - for food ingredients, nutraceuticals, cosmetics, enzymes, and industrial bioproducts. After a 2024 Chapter 11 restructuring, its assets were acquired by Pictor Biotech (led by ex-Novozymes executive Peter Rosholm) and unified in January 2025 with GPC Bio and Eleszto Genetika into a vertically integrated, 100+ person SynBio platform.
Cellares
Cellares is the first Integrated Development and Manufacturing Organization (IDMO) for cell therapy. Its Cell Shuttle - a fully automated, high-throughput platform roughly the size of a small conference room - replaces a warren of manual labs with one box that can run 16 patient batches in parallel, cutting labor and facility footprint by about 90 percent.
Stämm
Stämm is a deep-tech biomanufacturing company building a desktop-scale, 3D-printed, bubble-free bioprocessor that replaces the giant stainless-steel tanks of conventional pharma. Founded in Buenos Aires and headquartered in San Francisco, the company is pursuing a vision of decentralized, AI-driven production of biologics and cell therapies.